| Date Filed | Type | Description |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/25/2023 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 7.5% stake in Benitec Biopharma Inc. |
| 08/21/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 6.9% stake in Benitec Biopharma Inc. |
| 08/18/2023 |
SC 13G
| JANUS HENDERSON GROUP PLC reports a 9.9% stake in Benitec Biopharma Inc. |
| 08/18/2023 |
SC 13G/A
| Oliveira Steven Michael reports a 3.9% stake in §240.13d-2 Benitec Biopharma Inc. |
| 08/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and between Benitec Biopharma Inc. and Citizens JMP Securities, LLC",
"Form of Pre-Funded Warrant",
"Form of Common Warrant",
"Warrant Agency Agreement, by and between Benitec Biopharma Inc. and Computershare Trust Company, N.A",
"Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering HAYWARD, Calif., Aug. 08, 2023 — Benitec Biopharma Inc. , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 15,544,041 shares of its common stock and accompanying warrants to purchase up to 15,544,041 shares of common stock. Each share of common stock is being sold together with one common warrant to purchase one share of common stock at a combined offering price of $1.93 and each pre-funded warrant, if any, is being sold together with one common warrant to purchase one share of common stock at a combined off...",
"Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering HAYWARD, Calif., August 11, 2023 — Benitec Biopharma Inc. , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference “Silence and Replace” platform, today announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock and accompanying warrants to purchase up to 15,544,041 shares of common stock. Each share of common stock was sold together with one common warrant to purchase one share of common stock at a combined offering price of $1.93 and each pre-funded warrant was sold together with one common warrant to purchase one share of common stock at a combined offe..." |
|
| 08/10/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/10/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/07/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 08/03/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/31/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/18/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/08/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 02/14/2023 |
SC 13G/A
| CVI Investments, Inc. reports a 4.9% stake in Benitec Biopharma Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/23/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/20/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/12/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 11/10/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/25/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/18/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/14/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 10/11/2022 |
SC 13G
| FRANKLIN RESOURCES INC reports a 38.7% stake in BENITEC BIOPHARMA INC. |
| 10/07/2022 |
SC 13G/A
| Oliveira Steven Michael reports a 8.1% stake in §240.13d-2 Benitec Biopharma Inc. |
| 09/23/2022 |
SC 13G
| CVI Investments, Inc. reports a 5.8% stake in Benitec Biopharma Inc. |
|